Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
BioAtla logo in transparent PNG and vectorized SVG formats
BioAtla (NASDAQ:BCAB) versus Krystal Biotech (NASDAQ:KRYS) Head to Head ...
BioAtla rakes in $72.5M Series D, advancing research for pH-detecting ...
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M ...
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB ...
Bioatla Shares Surge on Strong Clinical and Financial Results - Stocks ...
BioAtla Q2 2025 Earnings Call and Business Update Scheduled for August ...
BioAtla Virtual KOL Event - IASLC Data Review: BA3011 in Non-Small Cell ...
BioAtla Join Forces with Context Therapeutics to Develop and ...
BioAtla Salaries | Levels.fyi
BioAtla & GATC Health: Oz-V Phase III Oncology Trial
BioAtla Secures FDA Alignment on Phase 3 Oz-V Cancer Drug Trial | BCAB ...
BioAtla (BCAB) Investor Presentation - Slideshow (NASDAQ:BCAB ...
BioAtla Careers | Levels.fyi
BioAtla Faces Financial Challenges Amid Promising Cancer Treatment ...
BioAtla and GATC Health Team Up to Drive Oz-V into Phase III Trial for ...
BioAtla Secures $40M for Ozuriftamab Vedotin Phase 3 Trial | AIM Media ...
Bioatla 2025 Q3 Earnings Net Loss Widens 49% to $15.8M
NEWS: BeiGene and BioAtla form worldwide collaboration to develop and ...
BioAtla and GATC Health Announce $40M SPV Transaction to Advance ...
BioAtla Announces cPR for BA3182 at 0.6 mg in Phase 1 Study | BCAB ...
BioAtla (BCAB|$17.7M) - 2024 Q4 & Full Year Earnings Analysis - YouTube
Conditionally Active Biologics™ (CAB) - BioAtla
BioAtla (BCAB) sets $40M SPV to fund Phase 3 Oz-V OPSCC trial | BCAB ...
BioAtla (BCAB) Surges 24% on FDA Alignment and Strategic Milestones ...
BioAtla Announces First Patient Treated In Trial for CAB-AXL-ADC ...
BioAtla out-licenses T cell therapy in $134 million deal ...
BioAtla Advances Phase 3 Oz-V Programme with Manufacturing-Ready SPV ...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results ...
BioAtla (BCAB.O) Plummets 15% Intraday—What’s Behind the Sudden Drop?
About Us | BioAtla
BioAtla Announces FDA Clearance of Investigational NDA for BA3011 ...
BioAtla Announces Regulatory Update on Clinical Development Plan for ...
Last week BioAtla announced a licensing agreement with Context ...
Clinical Trial Success Fuels BioAtla Stock Rally
BioAtla (BCAB.O) Sharp Intraday Drop: What’s Behind the 15% Plunge?
BioAtla Appoints James Allison, Ph.D. And Padmanee Sharma, M.D., Ph.D ...
BioAtla Stock Surges: FDA Greenlights Phase 3 Trial!
BioAtla Says FDA Clears IND Application For BA3361 For The Treatment Of ...
BioAtla (BCAB) Stock Price & Overview
BioAtla Virtual R&D Day: BA3071 CAB-CTLA-4 Phase 1 Data Review in ...
About Us - BioAtla
BioAtla Subsidiary, Himalaya Therapeutics, Will Develop And ...
BioAtla Presents Preliminary P-I Trial Data of BA3182 in Patients with ...
BioAtla 2026 Company Profile: Stock Performance & Earnings | PitchBook
BioAtla and GATC Health to advance Oz-V in Phase III trial
IPO BioAtla Inc (BCAB)
BioAtla August 2025 slides: promising clinical data amid financial ...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License ...
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment ...
Pfizer, BioAtla Sign Potential $1 Billion Biologics Deal - DCAT Value ...
Bioatla total assets 2024| Statista
Buy BioAtla stock | $BCAB Share Price | Lightyear
BioAtla Stock Surges: FDA Update Boosts Ozuriftamab Vedotin!
Bioatla Inc Stock Price ($BCAB), Quote & News | eToro
BioAtla Employee Perks & Benefits | Levels.fyi
IPO Alert: BioAtla (BCAB)
BioAtla Receives FDA Approval for BA3361 ADC - CTOL Digital Solutions
Conditionally Active Biologics™ (CAB) | BioAtla
BioAtla starts strategic review, plans 70% job cuts | BCAB Stock News
Bioatla Inc Stock Price Today | NASDAQ: BCAB Live - Investing.com
BioAtla gets FDA nod to start trials of BA3361, a CAB targeting Nectin ...
BioAtla and BeiGene Enter Collaboration to Develop BioAtla’s BA3071 ...
Bioatla Share Price - NAQ:BCAB Stock Research | Stockopedia
Portfolio Companies past | HBM Partners
BioAtla_百度百科
国外Biotech公司ADC产品技术特色
What Is BioAtla’s IPO Date and Price?
Logos of biotech companies
Exploring BioAtla, Inc. (BCAB): Who s Buying and Why? – DCFmodeling.com
Buy BioAtla, Inc Stock – BCAB Stock Quote Today & Investment Insights ...
BioAlta Yorkville
BioAtla’s AACR 2025 Breakthroughs: A New Frontier in Precision Oncology
BioAtla's Big Reveal: What to Expect from Q4 2024 Earnings
Clinical trial using BioAtla's Conditionally Active Biologics for ...
BeiGene Enters $269 Million Agreement for BioAtla’s CTLA-4 Inhibitor ...
CareCredit Headquarters & Corporate Office
Weekly digest 20 to 26 july 2024 - Optimal Dose
BioAtla, GATC create $40M SPV: Oz‑V pushed into registrational Phase 3 ...
NorthWest Biotherapeutics Inc (NWBO): How's your investment in $IOVA ...
BioAtla, Inc. (NASDAQ:BCAB) Q3 2025 Earnings Call Transcript
Bioatla宣布CAB-AXL-ADC產品IND申請獲得FDA批准丨醫麥優企秀 - 每日頭條
BioAtla, Inc. (BCAB) Stock Price, News, Quote & History - Yahoo Finance
Bioatla’s anti-Nectin-4 ADC gains IND clearance | BioWorld
Bioatla: The Most Undervalued Stock of 2025? - YouTube
BioAtla's Oz-V SPV Deal: A Strategic Financing Masterstroke in Oncology ...
BioAtla, Inc.のテクニカル分析(NASDAQ:BCAB) — TradingView
BioAtla’s Strategic Advancements and Promising Clinical Data Drive Buy ...
BioAtla条件性pH激活抗 EpCAM x CD3 双特异性抗体设计 - 知乎
BioAtla, Inc. (BCAB): Business Model Canvas – DCFmodeling.com
Biotech Venture Capital | Highlights | Boxer Capital
开发创新抗癌疗法！BioAtla完成7250万美元D轮融资，百济神州已与其达成合作 - 知乎
国内首家！BioAtla申报靶向ROR2的ADC - 知乎
BioAtla’s Ozuriftamab Vedotin and Its Pathway to Accelerated Approval ...
Context builds up bank of bispecific antibodies with up to $133M ...
Life Science Cares San Diego on LinkedIn: We are thrilled to announce ...
What Makes BioAtla's Presentation Design Effective in Communicating ...
BioAtla's Innovative Cancer Biologics | PDF | Medicine | Causes Of Death
BCAB (BioAtla, Inc.) – Technical Charts and Market Data – TrendSpider
BioAtla's (BCAB) Potential Gains Seen Despite Current Volatility.
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading ...
